2026 ICD-10-CM Diagnosis Code D76.1Hemophagocytic lymphohistiocytosis
ICD-10-CM Codes›D50–D89›D70-D77›D76
- Billable — Valid for Submission
- Chronic Condition
D76.1 is a billable ICD-10-CM diagnosis code for hemophagocytic lymphohistiocytosis. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026) and groups to MS-DRG 814 through 816. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Diseases of white blood cells.
Code Identity
Code Classification
Approximate SynonymsGuidance
Alternate terms and clinical phrases that map to this code.
- Acquired hemophagocytic lymphohistiocytosis associated with malignant disease
- Acquired pancytopenia
- Disorder of hematopoietic system in newborn
- Familial hemophagocytic lymphohistiocytosis
- Hemophagocytic lymphohistiocytosis
- Lipochrome histiocytosis - familial
- Macrophage activation syndrome
- Macrophage activation syndrome due to juvenile systemic onset arthritis
- Malignant white blood cell disorder
- Neonatal anemia
- Neonatal thrombocytopenia
- NOCARH syndrome
- Secondary hemophagocytic lymphohistiocytosis
Tabular List NotesGuidance
Coding notes and annotation back-references applicable to this code.
Inclusion Terms
- Familial hemophagocytic reticulosis
- Histiocytoses of mononuclear phagocytes
These terms are the conditions for which that code is to be used. The terms may be synonyms of the code title, or, in the case of "other specified" codes, the terms are a list of the various conditions assigned to that code. The inclusion terms are not necessarily exhaustive. Additional terms found only in the Alphabetic Index may also be assigned to a code.
Index to Diseases and InjuriesGuidance
Alphabetical index entries that point to this code.
- Histiocytosis - D76.3
- mononuclear phagocytes NEC - D76.1
- hemophagocytic, familial - D76.1
- Syndrome - See Also: Disease;
- macrophage activation - D76.1
External Cause of Injuries IndexGuidance
References for this code in the External Cause of Injuries Index.
- Histiocytosis
- mononuclear phagocytes NEC
- Lymphohistiocytosis, hemophagocytic(familial)
- Reticulosis(skin)
- hemophagocytic, familial
- Syndrome
- macrophage activation
Clinical ClassificationClinical
AHRQ’s CCSR groups this code into broader clinical categories.
Clinical InformationClinical
Macrophage Activation Syndrome
a serious complication of childhood systemic inflammatory disorders that is thought to be caused by excessive activation and proliferation of t-lymphocytes and macrophages. it is seen predominantly in children with systemic onset juvenile idiopathic arthritis.Grade 1 Secondary Hemophagocytic Lymphohistiocytosis, CTCAE
asymptomatic or mild symptoms; requiring clinical and/or diagnostic evaluation; intervention not indicatedGrade 2 Secondary Hemophagocytic Lymphohistiocytosis, CTCAE
moderate symptoms; intervention indicated (e.g., immunosuppressive agents)Grade 3 Secondary Hemophagocytic Lymphohistiocytosis, CTCAE
severe or medically significant but not immediately life threatening; hospitalization or prolongation of existing hospitalization indicatedGrade 4 Secondary Hemophagocytic Lymphohistiocytosis, CTCAE
life-threatening consequences; urgent intervention indicatedGrade 5 Secondary Hemophagocytic Lymphohistiocytosis, CTCAE
deathSecondary Hemophagocytic Lymphohistiocytosis, CTCAE
a disorder characterized by the development of a pathological and biochemical hyperinflammatory syndrome characterized by fever, cytopenias, hyperferritinemia, coagulopathy, hypofibrinogenemia and/or transaminitis and is attributable to therapy.Neonatal Alloimmune Thrombocytopenia|NAIT|Neonatal Thrombocytopenia due to Platelet Alloimmunization
thrombocytopenia that occurs in neonates as a consequence of transplacental passage of maternal alloantibodies directed against fetal platelet antigens.Neonatal Thrombocytopenia
a condition characterized by a decrease in the number of platelets in the blood below established reference ranges in a newborn.Secondary Hemophagocytic Lymphohistiocytosis
hemophagocytic lymphohistiocytosis due to infections, autoimmune disorders, or underlying malignancies. signs and symptoms include fever, lymphadenopathy, hepatomegaly, splenomegaly, and pancytopenia.Refractory Secondary Hemophagocytic Lymphohistiocytosis
secondary hemophagocytic lymphohistiocytosis that is resistant to treatment.
Patient EducationClinical
Familial hemophagocytic lymphohistiocytosis
Familial hemophagocytic lymphohistiocytosis is a disorder in which the immune system produces too many activated immune cells (lymphocytes) called T cells, natural killer cells, B cells, and macrophages (histiocytes). Excessive amounts of immune system proteins called cytokines are also produced.
Read the full article at MedlinePlus
Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.
Convert D76.1 to ICD-9-CMHistory
The closest ICD-9-CM equivalents under the General Equivalence Mappings.
Code HistoryHistory
Questions About D76.1Overview
Is D76.1 a billable code?
Yes. This is a billable ICD-10-CM code, specific enough to report hemophagocytic lymphohistiocytosis on HIPAA-covered claims from October 1, 2025 through September 30, 2026.
What MS-DRG does D76.1 group to?
When hemophagocytic lymphohistiocytosis is the principal diagnosis on an inpatient stay, it groups to MS-DRG 814, 815, 816, with relative weights from 0.6320 to 2.1267 depending on complications. Higher weights mean higher Medicare reimbursement.
What is the ICD-9 equivalent of D76.1?
Under the General Equivalence Mappings, hemophagocytic lymphohistiocytosis converts to ICD-9-CM 288.4 (hemophagocytic syndromes). The mapping is approximate, so confirm the match fits the documentation.
Footnotes
[1] Chronic - a chronic condition code indicates a condition lasting 12 months or longer and its effect on the patient based on one or both of the following criteria:
- The condition results in the need for ongoing intervention with medical products,treatment, services, and special equipment
- The condition places limitations on self-care, independent living, and social interactions.
